Evolus, Inc.(EOLS)

Drug Manufacturers - Specialty & Generic · Newport Beach, CA

$7.41-0.06 (-0.80%)

Delayed quote: Oct 6, 2026, 1:05 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T17:06:47.979Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:06:47.979Z.

Quote observation: 2026-10-06T17:05:12.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 487,983,705
Total debt · period ending 2026-06-30: 164,804,000
Cash · period ending 2026-06-30: 45,170,000
TTM operating EBITDA · period ending 2026-06-30: -13,277,000

FMP input reference: c1a6838803f42d6ea125a2cca62df7e150df7eb7d5f2d1fff74d5c1a91b3d340

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

EOLS EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

EOLS Competitors' EV/EBITDA Ratio

EOLS

Evolus, Inc.

Current

Market Cap

$487.98M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PBYI

Puma Biotechnology, Inc.

vs EOLS

Market Cap

$486.35M

EV/EBITDA Ratio

10.47x

TTM Avg

7.79x

3Y Avg

5.90x

5Y Avg

5.85x

OCS

Oculis Holding AG

vs EOLS

Market Cap

$495.60M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ARVN

Arvinas, Inc.

vs EOLS

Market Cap

$477.13M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CERS

Cerus Corporation

vs EOLS

Market Cap

$475.60M

EV/EBITDA Ratio

8097.24x

TTM Avg

8683.24x

3Y Avg

8683.24x

5Y Avg

8683.24x

DRUG

Bright Minds Biosciences Inc.

vs EOLS

Market Cap

$472.03M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALLO

Allogene Therapeutics, Inc.

vs EOLS

Market Cap

$510.79M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KMDA

Kamada Ltd.

vs EOLS

Market Cap

$471.36M

EV/EBITDA Ratio

10.52x

TTM Avg

9.91x

3Y Avg

9.78x

5Y Avg

16.95x

MASS

908 Devices Inc.

vs EOLS

Market Cap

$509.56M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CBIO

Crescent Biopharma, Inc.

vs EOLS

Market Cap

$509.02M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Evolus, Inc. (EOLS)	$487.98M	N/A	N/A	N/A	N/A
Puma Biotechnology, Inc. (PBYI)vs ›	$486.35M	10.47x	7.79x	5.90x	5.85x
Oculis Holding AG (OCS)vs ›	$495.60M	N/A	N/A	N/A	N/A
Arvinas, Inc. (ARVN)vs ›	$477.13M	N/A	N/A	N/A	N/A
Cerus Corporation (CERS)vs ›	$475.60M	8097.24x	8683.24x	8683.24x	8683.24x
Bright Minds Biosciences Inc. (DRUG)vs ›	$472.03M	N/A	N/A	N/A	N/A
Allogene Therapeutics, Inc. (ALLO)vs ›	$510.79M	N/A	N/A	N/A	N/A
Kamada Ltd. (KMDA)vs ›	$471.36M	10.52x	9.91x	9.78x	16.95x
908 Devices Inc. (MASS)vs ›	$509.56M	N/A	N/A	N/A	N/A
Crescent Biopharma, Inc. (CBIO)vs ›	$509.02M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics